If I was betting the future on genetics, I might hold on to my money til it gets extremely cheap to do full exome sequencing and medical records aggregation.
There’s probably going to be 20-40 companies doing both of these things. (Full exome sequencing and medical records aggregation).
In the interim, I’d focus on methodologies that revolve around collecting the attention and/or spit of sick people, twins, triplets, and quadruplets for as low as a cost as possible.
Blood generally presents issues, spit works better, or at least according to the molecular biologists I’ve spoken to.